Overview of the Annual General Meeting
Today, the annual general meeting of SciBase Holding AB (publ) took place, where significant decisions regarding the company’s future were made. SciBase, a pioneer in medical technology, is focused on groundbreaking innovations in dermatology with its advanced platform, Nevisense.
Key Resolutions Adopted
The meeting yielded important resolutions that reflect the company’s strategic direction:
- The adoption of the profit and loss statement along with the balance sheets for the financial year.
- No dividends will be distributed for the previous financial year, with profits being carried forward.
- The discharge from liability of the board and CEO concerning the past fiscal year was approved.
- The board will consist of four ordinary members with an auditor being selected from a registered accounting firm.
- Board member remuneration has been set, amounting to SEK 404,000 for the chairman and SEK 135,000 for each of the other members.
- Re-election of current board members and the election of a new member were confirmed, ensuring diverse leadership experience.
- Principles for the nomination committee’s formation were formalized.
- An incentive program was adopted that includes a directed issue of warrants.
- Amendments to the articles of association regarding share capital limits were ratified.
- Authority was granted to the board to increase share capital via new share issuance.
New Board Members and Future Directions
The election of new board members represents a strategic move to bolster both expertise and governance. This includes the re-election of Jeper Høiland as chairman, alongside members such as Robert Molander and Diana Ferro. They bring a wealth of knowledge that promises to guide SciBase toward continued innovation in the skin health sector.
About SciBase
SciBase is at the forefront of medical technology, dedicated to the early detection and prevention of skin-related conditions. Leveraging AI and advanced electrical impedance spectroscopy technology, Nevisense enhances diagnostic efficiency, critical for effective management of skin health. With over two decades of backed research, the company is recognized as a leader from the esteemed Karolinska Institute.
Commitment to Innovation
The company's primary aim is patient welfare, advocating for timely interventions that minimize suffering and healthcare expenses. This commitment highlights SciBase's role not only in improving lives but also in reducing the financial burden on healthcare systems.
Company Information
Having been listed on the Nasdaq First North Growth Market since June 2, 2015, SciBase continues to expand its presence in the global market. For further insights and updates about SciBase's innovative journey, you can visit their official website.
Frequently Asked Questions
What resolutions were adopted during the annual meeting?
The meeting approved several key resolutions, including board member elections and an incentive program for the company.
Who were the newly elected members of the board?
The meeting resulted in the re-election of Jesper Høiland and the election of Anna Eriksrud as a new board member.
What is the main focus of SciBase?
SciBase specializes in early detection techniques in dermatology, particularly through its AI-integrated platform, Nevisense.
What is the current status of SciBase’s share capital?
The company amended its articles to adjust the share capital range, setting it between SEK 16,914,781.65 and SEK 67,659,126.60.
How can one learn more about SciBase’s operations?
Further detailed information about the company's initiatives and updates can be found on their official website.
